Page last updated: 2024-11-12
montanine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
montanine: has anxiolytic, antidepressant, and anticonvulsant activities [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 11087935 |
| CHEMBL ID | 1221863 |
| SCHEMBL ID | 812255 |
| MeSH ID | M0506799 |
Synonyms (11)
| Synonym |
|---|
| CHEMBL1221863 |
| montanine |
| (-)-montanine |
| 642-52-4 |
| SCHEMBL812255 |
| bdbm50190649 |
| (6r,6as,8s,9s,11s)-5,6a,7,8,9,11-hexahydro-9-methoxy-6,11-methano-6h-benzo[b]-1,3-benzodioxolo[5,6-e]azepin-8-ol |
| DTXSID801107687 |
| (1s,13s,15s,16s)-16-methoxy-5,7-dioxa-12-azapentacyclo[10.6.1.02,10.04,8.013,18]nonadeca-2,4(8),9,17-tetraen-15-ol |
| compound np-016462 |
| AKOS040738613 |
Research Excerpts
Overview
Montanine is an alkaloid isolated from Rhodophiala bifida bulb with potential anti-arthritic activity.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Montanine is an alkaloid isolated from Rhodophiala bifida bulb with potential anti-arthritic activity. " | ( Disease modifying anti-rheumatic activity of the alkaloid montanine on experimental arthritis and fibroblast-like synoviocytes. Clarimundo, VS; de Oliveira, PG; Farinon, M; Gulko, PS; Pedrazza, GP; Xavier, RM; Zuanazzi, JA, 2017) | 2.14 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (4)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Acetylcholinesterase | Electrophorus electricus (electric eel) | IC50 (µMol) | 200.0000 | 0.0000 | 0.9453 | 9.9400 | AID1315225 |
| Cholinesterase | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0000 | 1.5599 | 10.0000 | AID1807566 |
| Acetylcholinesterase | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0000 | 0.9332 | 10.0000 | AID1807563 |
| Cholinesterase | Equus caballus (horse) | IC50 (µMol) | 200.0000 | 0.0000 | 2.2214 | 9.4000 | AID1315224 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (25)
Molecular Functions (15)
Ceullar Components (16)
Bioassays (12)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1366161 | Antibacterial activity against Staphylococcus epidermidis | 2017 | Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22 | Antibacterial constituents of the plant family Amaryllidaceae. |
| AID501441 | Inhibition of AChE at 10 uM by Ellman's assay | 2010 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17 | Structure-activity studies on acetylcholinesterase inhibition in the lycorine series of Amaryllidaceae alkaloids. |
| AID1807562 | Inhibition of human AChE at 100 uM using acetylthiocholine as substrate by Ellman's method | 2021 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 51 | Derivatives of montanine-type alkaloids and their implication for the treatment of Alzheimer's disease: Synthesis, biological activity and in silico study. |
| AID1366152 | Antibacterial activity against Staphylococcus aureus | 2017 | Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22 | Antibacterial constituents of the plant family Amaryllidaceae. |
| AID1578099 | Antiplasmodial activity against Trichomonas vaginalis assessed as reduction in plasmodium viability at 125 ug/ml relative to control | 2019 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20 | Antiprotozoal alkaloid principles of the plant family Amaryllidaceae. |
| AID1807563 | Inhibition of human AChE using acetylthiocholine as substrate by Ellman's method | 2021 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 51 | Derivatives of montanine-type alkaloids and their implication for the treatment of Alzheimer's disease: Synthesis, biological activity and in silico study. |
| AID1807566 | Inhibition of human BuChE using butyrylthiocholine chloride as substrate by Ellman's method | 2021 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 51 | Derivatives of montanine-type alkaloids and their implication for the treatment of Alzheimer's disease: Synthesis, biological activity and in silico study. |
| AID1807565 | Inhibition of human BuChE at 100 uM using butyrylthiocholine chloride as substrate by Ellman's method | 2021 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 51 | Derivatives of montanine-type alkaloids and their implication for the treatment of Alzheimer's disease: Synthesis, biological activity and in silico study. |
| AID1366151 | Antibacterial activity against Pseudomonas aeruginosa | 2017 | Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22 | Antibacterial constituents of the plant family Amaryllidaceae. |
| AID1366148 | Antibacterial activity against Escherichia coli | 2017 | Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22 | Antibacterial constituents of the plant family Amaryllidaceae. |
| AID1315224 | Inhibition of equine serum BuChE using ATCI as substrate preincubated for 30 mins followed by substrate addition measured after 5 mins by DTNB-based spectrophotometric analysis | 2016 | Journal of natural products, 05-27, Volume: 79, Issue:5 | Alkaloids from Hippeastrum argentinum and Their Cholinesterase-Inhibitory Activities: An in Vitro and in Silico Study. |
| AID1315225 | Inhibition of electric eel AChE using ATCI as substrate preincubated for 30 mins followed by substrate addition measured after 5 mins by DTNB-based spectrophotometric analysis | 2016 | Journal of natural products, 05-27, Volume: 79, Issue:5 | Alkaloids from Hippeastrum argentinum and Their Cholinesterase-Inhibitory Activities: An in Vitro and in Silico Study. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (18)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 10 (55.56) | 24.3611 |
| 2020's | 3 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 26.38
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.38) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 3 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||